Liminal BioSciences Inc. has completed its statutory plan of arrangement with Structured Alpha LP (SALP), a limited partnership managed by Thomvest Asset Management Ltd. SALP has acquired all issued and outstanding common shares of Liminal BioSciences, not already owned by SALP or its affiliates, at a price of US$8.50 per share in cash. Shareholders must follow specific instructions to receive their entitlements. Following the arrangement, Liminal BioSciences will delist from the Nasdaq Capital Market and cease to be a reporting issuer under Canadian and U.S. securities laws.
Liminal BioSciences Inc. (“Liminal BioSciences” or the “Company”) is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP (“SALP”), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier today (the “Arrangement”). Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences (the “Shares”) not currently owned by SALP or its affiliates and associates (the “Minority Shares”) at a price of US$8.50 per Share, payable in cash (the “Consideration”).
Registered holders of Minority Shares (“Minority Shareholders”) are reminded that in order to receive any Consideration that they are entitled to, they must properly complete, sign and return the letter of transmittal to Computershare Investor Services Inc., as depositary, together with the share certificate(s) and/or Direct Registration System (DRS) Advice(s) representing Shares formerly held by them. Minority Shareholders who hold their Shares through a broker, investment dealer or other intermediary should carefully follow the instructions provided by such broker, investment dealer or other intermediary.
As a result of the Arrangement, the Shares will no longer be listed on the Nasdaq Capital Market. In addition, the Company will submit an application to cease to be a reporting issuer under applicable Canadian securities law, will file a certification and notice on Form 15 with the U.S. Securities and Exchange Commission to suspend its reporting obligations under U.S. securities laws and will otherwise terminate the Company’s public reporting requirements.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace